Biotech | January 05, 2022
Biogen exercises option with Ionis for spinal muscular atrophy
Biogen paid Ionis a US $ 60 million one-time upfront payment
Biogen paid Ionis a US $ 60 million one-time upfront payment
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
New Board of Directors and management team at Suven Pharma also appointed
Subscribe To Our Newsletter & Stay Updated
